AZN supply chain intelligence for AstraZeneca PLC: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
AstraZeneca PLC (AZN) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| CGEN | Compugen Ltd. | 92% | Reciprocal relationship from CGEN graph: Under the terms of the license agreement, as amended (including most recently as December 16, 2025), we provided an exclusive license to AstraZeneca to use ou… |
| HBIO | Harvard Bioscience, Inc. | 92% | Reciprocal relationship from HBIO graph: Reciprocal relationship from AZN graph: Reciprocal relationship from HBIO graph: Reciprocal relationship from AZN graph: Reciprocal relationship from HBIO gra… |
| IONS | Ionis Pharmaceuticals, Inc. | 92% | Reciprocal relationship from IONS graph: We determined that we had a vendor-customer relationship within the scope of ASC Topic 606, Revenue from Contracts with Customers, or ASC 606, for the license… |
| IRWD | Ironwood Pharmaceuticals, Inc. | 92% | Reciprocal relationship from IRWD graph: Reciprocal relationship from AZN graph: Reciprocal relationship from IRWD graph: Under the collaboration agreement, AstraZeneca is required to pay tiered roya… |
| SLN | Silence Therapeutics plc | 92% | Reciprocal relationship from SLN graph: In March 2020, we entered into a collaboration agreement with AstraZeneca to discover, develop and commercialize siRNA therapeutics for the treatment of cardio… |
| KYNB | Kyntra Bio, Inc. | 85% | Reciprocal relationship from KYNB graph: Reciprocal relationship from AZN graph: Reciprocal relationship from KYNB graph: Reciprocal relationship from AZN graph: Reciprocal relationship from KYNB gra… |
| ALLO | Allogene Therapeutics, Inc. | 72% | Reciprocal relationship from ALLO graph: y suffer if government and other third-party payors fail to provide coverage and adequate reimbursement. We expect downward pressure on pharmaceutical pricing… |
| ALLR | Allarity Therapeutics, Inc. | 72% | Reciprocal relationship from ALLR graph: Reciprocal relationship from AZN graph: Reciprocal relationship from ALLR graph: Reciprocal relationship from AZN graph: Reciprocal relationship from ALLR gra… |
| ALNY | Alnylam Pharmaceuticals, Inc. | 72% | Reciprocal relationship from ALNY graph: Reciprocal relationship from AZN graph: Reciprocal relationship from ALNY graph: Reciprocal relationship from AZN graph: Reciprocal relationship from ALNY gra… |
| APRE | Aprea Therapeutics, Inc. | 72% | Reciprocal relationship from APRE graph: Reciprocal relationship from AZN graph: Reciprocal relationship from APRE graph: Reciprocal relationship from AZN graph: Reciprocal relationship from APRE gra… |
| ARGX | argenx SE | 72% | Reciprocal relationship from ARGX graph: more than 26 years of experience in quality assurance within the pharmaceutical industry. Most recently, Ms. Wilk served as senior director, head of medical, … |
| ASML | ASML Holding N.V. | 72% | Reciprocal relationship from ASML graph: Reciprocal relationship from AZN graph: Reciprocal relationship from ASML graph: hief Strategic Sourcing & Procurement Officer Term expires 2027 Executive Vic… |
| BCAX | Bicara Therapeutics Inc. | 72% | Reciprocal relationship from BCAX graph: inancial institutions where we maintain our cash, cash equivalents and marketable securities, there can be no assurance that we would be able to access uninsu… |
| CCCC | C4 Therapeutics, Inc. | 72% | Reciprocal relationship from CCCC graph: ies and no experience in marketing products. We intend to develop an in-house marketing organization and sales force, which will require significant capital e… |
| CDXS | Codexis, Inc. | 72% | Reciprocal relationship from CDXS graph: Reciprocal relationship from AZN graph: Reciprocal relationship from CDXS graph: Reciprocal relationship from AZN graph: Reciprocal relationship from CDXS gra… |
| CHRS | Coherus Oncology, Inc. | 72% | Reciprocal relationship from CHRS graph: oduct is manufactured or disagrees with the promotion, marketing or labeling of a product, such regulatory agency may impose restrictions on that product or u… |
| CPMV | Mosaic ImmunoEngineering, Inc. | 72% | Reciprocal relationship from CPMV graph: Reciprocal relationship from AZN graph: Reciprocal relationship from CPMV graph: Reciprocal relationship from AZN graph: Reciprocal relationship from CPMV gra… |
| CRBP | Corbus Pharmaceuticals Holdings, Inc. | 72% | Reciprocal relationship from CRBP graph: designed to be an improved next-generation site-specific Nectin-4 targeting antibody drug conjugate. CRB-701 is a monoclonal antibody attached to an MMAE cyto… |
| CRNX | Crinetics Pharmaceuticals, Inc. | 72% | Reciprocal relationship from CRNX graph: products in relation to alternative treatments and therapies; • our ability to obtain and maintain sufficient third-party coverage and adequate reimbursement … |
| CTMX | CytomX Therapeutics, Inc. | 72% | Reciprocal relationship from CTMX graph: h activities and efforts to establish and run clinical trials for Varseta-M and CX-801. However, in January 2025, we announced that we would reduce our workfo… |
| CTNM | Contineum Therapeutics, Inc. | 72% | Reciprocal relationship from CTNM graph: om, or engaging in the sale or supply of products and services to, U.S. sanctioned countries, governments, persons and entities. Violations of Trade Laws can … |
| CYTK | Cytokinetics, Incorporated | 72% | Reciprocal relationship from CYTK graph: ging pharmacology could result in an expansion of our business franchise with the development and potential approval of ulacamten for the treatment of a subse… |
| DEO | Diageo plc | 72% | Reciprocal relationship from DEO graph: Reciprocal relationship from AZN graph: Reciprocal relationship from DEO graph: Reciprocal relationship from AZN graph: Reciprocal relationship from DEO graph:… |
| DRTS | Alpha Tau Medical Ltd. | 72% | Reciprocal relationship from DRTS graph: e term sheets, effective for a 15-year term following the approval to sell our products, Medison will be responsible for performing regulatory submissions, ma… |
| DRTSW | DRTSW | 72% | Reciprocal relationship from DRTSW graph: Reciprocal relationship from AZN graph: Reciprocal relationship from DRTSW graph: Reciprocal relationship from AZN graph: Reciprocal relationship from DRTSW … |
| FBIOP | FBIOP | 72% | Reciprocal relationship from FBIOP graph: Reciprocal relationship from AZN graph: Reciprocal relationship from FBIOP graph: Reciprocal relationship from AZN graph: Reciprocal relationship from FBIOP … |
| IDYA | IDEAYA Biosciences, Inc. | 72% | Reciprocal relationship from IDYA graph: Reciprocal relationship from AZN graph: Reciprocal relationship from IDYA graph: Reciprocal relationship from AZN graph: Reciprocal relationship from IDYA gra… |
| KNSA | Kiniksa Pharmaceuticals International, plc | 72% | Reciprocal relationship from KNSA graph: velop and commercialize ARCALYST worldwide, excluding the Middle East and North Africa, for all indications other than those in oncology and local administrat… |
| MGNX | MacroGenics, Inc. | 72% | Reciprocal relationship from MGNX graph: n exclusive option to license worldwide rights to the research program, upon achievement of a pre-defined preclinical milestone. HIV DART Molecules We conduct… |
| MRK | Merck & Co., Inc. | 72% | Reciprocal relationship from MRK graph: Reciprocal relationship from AZN graph: Reciprocal relationship from MRK graph: Reciprocal relationship from AZN graph: Reciprocal relationship from MRK graph:… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| IDYA | IDEAYA Biosciences, Inc. | 92% | Reciprocal relationship from IDYA graph: Reciprocal relationship from AZN graph: Reciprocal relationship from IDYA graph: Reciprocal relationship from AZN graph: Reciprocal relationship from IDYA gra… |
| CLLS | Cellectis S.A. | 90% | Reciprocal relationship from CLLS graph: Reciprocal relationship from AZN graph: Reciprocal relationship from CLLS graph: We have entered into licensing or collaboration agreements with partners, suc… |
| FBIO | Fortress Biotech, Inc. | 90% | Reciprocal relationship from FBIO graph: Reciprocal relationship from AZN graph: Reciprocal relationship from FBIO graph: Reciprocal relationship from AZN graph: Reciprocal relationship from FBIO gra… |
| IPHA | Innate Pharma S.A. | 90% | Reciprocal relationship from IPHA graph: The Company has significant collaborations with AstraZeneca for the development of monalizumab and IPH5201. |
| SLN | Silence Therapeutics plc | 90% | Reciprocal relationship from SLN graph: Under this agreement, AstraZeneca made an upfront cash payment to us of $20.0 million in May 2020. |
| ALLR | Allarity Therapeutics, Inc. | 72% | Reciprocal relationship from ALLR graph: Reciprocal relationship from AZN graph: Reciprocal relationship from ALLR graph: ting the need for us to invest in our own manufacturing facilities, equipment… |
| APRE | Aprea Therapeutics, Inc. | 72% | Reciprocal relationship from APRE graph: Reciprocal relationship from AZN graph: Reciprocal relationship from APRE graph: Reciprocal relationship from AZN graph: Reciprocal relationship from APRE gra… |
| BMY | Bristol-Myers Squibb Company | 72% | of these relate to the Medicaid and state programmes with an adjustment in respect of prior year net US Product Sales in 2025 of 0.2 % (2024: 0.1 %; 2023: 0.3 %) and Managed Care and Medicare of 0.4 … |
| BMY | Bristol-Myers Squibb Company | 72% | Reciprocal relationship from BMY graph: Reciprocal relationship from AZN graph: of these relate to the Medicaid and state programmes with an adjustment in respect of prior year net US Product Sales i… |
| BMYMP | Bristol-Myers Squibb Co | 72% | Reciprocal relationship from BMYMP graph: Reciprocal relationship from AZN graph: of these relate to the Medicaid and state programmes with an adjustment in respect of prior year net US Product Sales… |
| BMYMP | Bristol-Myers Squibb Co | 72% | of these relate to the Medicaid and state programmes with an adjustment in respect of prior year net US Product Sales in 2025 of 0.2 % (2024: 0.1 %; 2023: 0.3 %) and Managed Care and Medicare of 0.4 … |
| CDXS | Codexis, Inc. | 72% | Reciprocal relationship from CDXS graph: Reciprocal relationship from AZN graph: Reciprocal relationship from CDXS graph: Reciprocal relationship from AZN graph: Reciprocal relationship from CDXS gra… |
| CHRS | Coherus Oncology, Inc. | 72% | Reciprocal relationship from CHRS graph: Reciprocal relationship from AZN graph: Reciprocal relationship from CHRS graph: Reciprocal relationship from AZN graph: Reciprocal relationship from CHRS gra… |
| CORT | Corcept Therapeutics Incorporated | 72% | Reciprocal relationship from CORT graph: Reciprocal relationship from AZN graph: Reciprocal relationship from CORT graph: Reciprocal relationship from AZN graph: Reciprocal relationship from CORT gra… |
| CRBP | Corbus Pharmaceuticals Holdings, Inc. | 72% | Reciprocal relationship from CRBP graph: Reciprocal relationship from AZN graph: Reciprocal relationship from CRBP graph: Reciprocal relationship from AZN graph: Reciprocal relationship from CRBP gra… |
| CTMX | CytomX Therapeutics, Inc. | 72% | Reciprocal relationship from CTMX graph: tivities and efforts to establish and run clinical trials for CX-2051, CX-904 and CX-801. However, in January 2025, we announced that we would reduce our work… |
| CYTK | Cytokinetics, Incorporated | 72% | Reciprocal relationship from CYTK graph: Reciprocal relationship from AZN graph: Reciprocal relationship from CYTK graph: Reciprocal relationship from AZN graph: Reciprocal relationship from CYTK gra… |
| DRTSW | DRTSW | 72% | Reciprocal relationship from DRTSW graph: nding term sheets with Medison Pharma Ltd., one of the largest commercial partners of leading global biotech companies in international markets, and its affi… |
| GLSI | Greenwich LifeSciences, Inc. | 72% | Reciprocal relationship from GLSI graph: duct candidate and the average exposure time in the clinical development program may be inadequate to detect rare adverse events or chance findings that may o… |
| KYNB | Kyntra Bio, Inc. | 72% | Reciprocal relationship from KYNB graph: straZeneca for the development and commercialization of roxadustat. For the years ended December 31, 2024 and 2023, our revenue for continuing operations was … |
| MGNX | MacroGenics, Inc. | 72% | Reciprocal relationship from MGNX graph: t and future product candidates. Most of the principal materials we use in our manufacturing operations are available from more than one source. However, we o… |
| MTVA | MetaVia Inc. | 72% | Reciprocal relationship from MTVA graph: ing. Accordingly, shares registered under such registration statements will be available for sale in the open market. In the future, we may also issue our sec… |
| NUVB | Nuvation Bio Inc. | 72% | Reciprocal relationship from NUVB graph: t of our investigational products. We currently have a single source for taletrectinib API and drug product, and we obtain taletrectinib API pursuant to a lon… |
| PLRX | Pliant Therapeutics, Inc. | 72% | Reciprocal relationship from PLRX graph: approval of our product candidates and jeopardize our ability to commercialize our product candidates and generate revenue. In addition, there are risks assoc… |
| PPCB | Propanc Biopharma, Inc. | 72% | Reciprocal relationship from PPCB graph: novel expression system and are also in the process of optimizing conditions to achieve high titers of recombinant trypsinogen and chymotrypsinogen. Further, … |
| PRRUF | PRRUF | 72% | Reciprocal relationship from PRRUF graph: . 28 Table of Contents IMP761 Preclinical Development On January 3, 2017 we announced a new early stage product candidate to be known as IMP761, developed in… |
| PYXS | Pyxis Oncology, Inc. | 72% | Reciprocal relationship from PYXS graph: ter prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitab… |
| RCUS | Arcus Biosciences, Inc. | 72% | Reciprocal relationship from RCUS graph: nd clinical testing. If any of our optioned investigational products obtain marketing approval, we expect to continue to use third-party manufacturers along w… |
| SNYNF | Sanofi | 72% | Reciprocal relationship from SNYNF graph: Reciprocal relationship from AZN graph: t of F-14 these relate to the Medicaid and state programmes with an adjustment in respect of prior year net US Produc… |
| SNYNF | Sanofi | 72% | t of F-14 these relate to the Medicaid and state programmes with an adjustment in respect of prior year net US Product Sales in 2024 of 0.1 % (2023: 0.3 %; 2022: 0.5 %) and Managed Care and Medicare … |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| AZN-DEBT | Debt stack $34.0B | 90% | Market cache reports total debt of $34.0B. |
| Acquired Entity | Name | Confidence | Evidence |
|---|---|---|---|
| AZN-ACQ-0001654954-26-001966 | Pascal Soriot acquired 101,495 ordinary shares under the AstraZeneca Performance Share Plan. | 85% | Pascal Soriot acquired 101,495 ordinary shares under the AstraZeneca Performance Share Plan. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| AZN-OWNER-CAPITAL-INTERNATIONAL-INVESTORS | Capital International Investors | 95% | 13F/ownership overlay lists Capital International Investors; shares held 25,052,520; ownership 0.95%; value $4.7B; as of 2025-09-30. |
| AZN-OWNER-SARANAC-PARTNERS-LTD | Saranac Partners Ltd | 95% | 13F/ownership overlay lists Saranac Partners Ltd; shares held 5,817; value $1.1M; as of 2025-09-30. |
| AZN-OWNER-FISHER-ASSET-MANAGEMENT-LLC | Fisher Asset Management, LLC | 95% | 13F/ownership overlay lists Fisher Asset Management, LLC; shares held 21,162,724; ownership 0.81%; value $4.0B; as of 2025-09-30. |
| AZN-OWNER-PRICE-T-ROWE-ASSOCIATES-INC | Price (T.Rowe) Associates Inc | 95% | 13F/ownership overlay lists Price (T.Rowe) Associates Inc; shares held 49,124,476; ownership 1.87%; value $9.3B; as of 2025-09-30. |
| AZN-OWNER-FMR-LLC | FMR, LLC | 95% | 13F/ownership overlay lists FMR, LLC; shares held 21,686,320; ownership 0.83%; value $4.1B; as of 2025-09-30. |
| AZN-OWNER-GOLDMAN-SACHS-GROUP-INC | Goldman Sachs Group Inc | 95% | 13F/ownership overlay lists Goldman Sachs Group Inc; shares held 13,671,749; ownership 0.52%; value $2.6B; as of 2025-09-30. |
| AZN-OWNER-PACER-ADVISORS-INC | Pacer Advisors, Inc. | 95% | 13F/ownership overlay lists Pacer Advisors, Inc.; shares held 15,863; value $3.0M; as of 2025-09-30. |
| AZN-OWNER-BANK-OF-AMERICA-CORPORATION | Bank of America Corporation | 95% | 13F/ownership overlay lists Bank of America Corporation; shares held 32,633,139; ownership 1.24%; value $6.1B; as of 2025-09-30. |
| AZN-OWNER-SANDERS-CAPITAL-LLC | Sanders Capital, LLC | 95% | 13F/ownership overlay lists Sanders Capital, LLC; shares held 14,058,682; ownership 0.54%; value $2.6B; as of 2025-09-30. |
| AZN-OWNER-FNY-INVESTMENT-ADVISERS-LLC | FNY Investment Advisers, LLC | 95% | 13F/ownership overlay lists FNY Investment Advisers, LLC; shares held 200; value $37,979; as of 2025-12-31. |
| AZN-OWNER-FRANKLIN-RESOURCES-INC | Franklin Resources, Inc. | 95% | 13F/ownership overlay lists Franklin Resources, Inc.; shares held 19,714,165; ownership 0.75%; value $3.7B; as of 2025-09-30. |
| AZN-OWNER-PRIMECAP-MANAGEMENT-COMPANY | Primecap Management Company | 95% | 13F/ownership overlay lists Primecap Management Company; shares held 39,857,971; ownership 1.52%; value $7.5B; as of 2025-09-30. |
| AZN-OWNER-PARADIGM-ASSET-MANAGEMENT-COMPANY-LLC | Paradigm Asset Management Company, LLC | 95% | 13F/ownership overlay lists Paradigm Asset Management Company, LLC; shares held 13,100; value $2.5M; as of 2025-09-30. |
| AZN-OWNER-WELLINGTON-MANAGEMENT-GROUP-LLP | Wellington Management Group, LLP | 95% | 13F/ownership overlay lists Wellington Management Group, LLP; shares held 32,299,561; ownership 1.23%; value $6.1B; as of 2025-09-30. |
| AZN-OWNER-OLD-MISSION-CAPITAL-LLC | Old Mission Capital, LLC | 95% | 13F/ownership overlay lists Old Mission Capital, LLC; shares held 59,639; value $11.3M; as of 2025-09-30. |
| AZN-OWNER-BARCLAYS-PLC | BARCLAYS PLC | 90% | 13F overlay lists BARCLAYS PLC as top holder; 1 tracked holders. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| CYTOF | Altamira Therapeutics Ltd. | 100.00 | 2 | |
| BEAM | Beam Therapeutics Inc. | 100.00 | 2 | |
| DEO | Diageo plc | 100.00 | 1 | ['supplier'] |
| EMMA | Emmaus Life Sciences, Inc. | 100.00 | 2 | |
| BIOA | BioAge Labs, Inc. | 100.00 | 2 | |
| CYTK | Cytokinetics, Incorporated | 100.00 | 1 | ['customer', 'supplier'] |
| CRBP | Corbus Pharmaceuticals Holdings, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| AUTL | Autolus Therapeutics plc | 100.00 | 2 | |
| BLRX | BioLineRx Ltd. | 100.00 | 2 | |
| CTNM | Contineum Therapeutics, Inc. | 100.00 | 1 | ['supplier'] |
| DFTX | Definium Therapeutics, Inc. | 100.00 | 2 | |
| IHG | InterContinental Hotels Group PLC | 100.00 | 2 | |
| ANL | Adlai Nortye Ltd. | 100.00 | 2 | |
| BORAY | Bora Pharmaceuticals Co., Ltd. | 100.00 | 2 | |
| CLYM | Climb Bio, Inc. | 100.00 | 2 | |
| ALXO | ALX Oncology Holdings Inc. | 100.00 | 2 | |
| ANRO | Alto Neuroscience, Inc. | 100.00 | 2 | |
| AXSM | Axsome Therapeutics, Inc. | 100.00 | 2 | |
| BSX | Boston Scientific Corporation | 100.00 | 2 | |
| CBIO | Crescent Biopharma, Inc. | 100.00 | 2 |